Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsSystematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus IsolatesRelationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infectionsCoagulase-negative staphylococci.A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.Prognosis of patients with methicillin-resistant Staphylococcus aureus bloodstream infection treated with teicoplanin: a retrospective cohort study investigating effect of teicoplanin minimum inhibitory concentrations.Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution methodDetection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.Characterization of methicillin-resistant Staphylococcus aureus isolates from patients with persistent or recurrent bacteremia.USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban DetroitObservation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis.Difference in agr dysfunction and reduced vancomycin susceptibility between MRSA bacteremia involving SCCmec types IV/IVa and I-III.Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients.Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. auClinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia.High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus.Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care unitsPredictors of mortality in Staphylococcus aureus BacteremiaPersistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates.Predicting risk for death from MRSA bacteremia.The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysisSerine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureusCharacteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer centerMechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream InfectionEffects of aggregate and individual antibiotic exposure on vancomycin MICs for Staphylococcus aureus isolates recovered from pediatric patientsVancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.Predictors and clinical outcomes of persistent methicillin-resistant Staphylococcus aureus bacteremia: a prospective observational study.Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolatesThe clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.
P2860
Q24646677-44ECE16F-C157-46FB-9570-3F08069E9FC3Q26796560-8BD5FFEA-24E7-403D-96A6-91D9C156B3DBQ27011138-636027BB-EE0F-4998-B886-EB13D28590E7Q30401758-F0FD1F9E-FBFB-47DD-8CD7-C2080FAF2DFAQ30455758-D9D24DC5-7DCF-4151-BF8A-DB060E49F917Q33407156-C9A2D292-AFE3-425E-9B15-BBA222E72136Q33596888-CD96515C-6D25-4BC4-ABD6-D5BF59A400A2Q33613735-6B9CA328-51CD-4F1F-8509-2B359745E82BQ33640218-14797355-E4AC-466F-B996-C35E0A5EABC2Q33909407-7DED9D0E-8C45-464F-9087-7E3DC774C631Q33939095-85956832-304C-42B1-B938-42EDF17107BEQ33945397-E76584C1-5955-4817-BB4A-2C30F37E7440Q34091829-4363E24A-F4B0-4B8E-9B86-53155014B4E6Q34454418-0E9DBC3F-8288-4DED-91D9-B582E0605490Q34477769-2AC1A11E-82DA-437C-AFA4-429FBF57D18FQ34494676-09ACE554-06CC-419C-B778-7BDAAEE69DFDQ34998629-229E5E74-3466-4901-9A62-9C9471FC58BCQ35064413-982578D0-1D96-4F73-A1E9-2FF1E6EEF2DEQ35066896-31456151-92DE-4AF9-AEE5-E8A1BE7AB071Q35607912-8FF3C44D-109A-4C0C-A0D4-E28FB8B821C9Q35806306-185A5A2A-B2A4-4794-9075-974373AC1165Q35819831-624DAC63-D37A-4241-B10D-019501E9F2D9Q35940556-FD536E0E-941B-4ADF-A349-B1BEC455E875Q36008997-DE31253E-0009-4E8E-BB79-44DE8E78F5A7Q36037687-51EFC086-BA97-43BA-9EC0-A154D03BFD04Q36148828-BCAE3A29-4449-4664-911F-81285D1BA257Q36153912-6B38D93C-F9CD-4D0C-81FC-3B669D70AC1DQ36349620-35930C98-0783-4253-8984-C938E0017C79Q36565462-EF9898F5-99D0-4903-9CC1-15962B1AA9B0Q36636699-F9D0FE07-1DD6-4DDD-A4CE-C848CA0D3AEEQ36644689-68C02E09-5CA0-47B7-901D-945F172EAE6BQ36757645-7A940FB6-EF4B-4953-AEA0-D9B6084A6AA9Q36856946-C3747386-E1BC-406C-800E-3AAB5F94EF43Q37124131-572FF3E7-ADFF-4216-802B-87920A98DCE6Q37125081-CAED54E0-3DA8-403D-AE49-43C8F755769CQ37203845-9C6E7BAD-4827-4976-BF46-1DDEE54EF176Q37263399-35E41134-8BEC-49BC-96D8-8039E61C6231Q37356506-A862B413-D53F-4CB4-8D5F-D352748D4589Q37809666-0FAA36DE-4B4F-476A-A78C-9533AAC1695AQ37981103-2C25C637-6F01-44A5-BD54-DCD71BF5626F
P2860
Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Vancomycin MIC plus heteroresi ...... teremia: trends over 11 years.
@en
Vancomycin MIC plus heteroresi ...... teremia: trends over 11 years.
@nl
type
label
Vancomycin MIC plus heteroresi ...... teremia: trends over 11 years.
@en
Vancomycin MIC plus heteroresi ...... teremia: trends over 11 years.
@nl
prefLabel
Vancomycin MIC plus heteroresi ...... teremia: trends over 11 years.
@en
Vancomycin MIC plus heteroresi ...... teremia: trends over 11 years.
@nl
P2093
P2860
P356
P1476
Vancomycin MIC plus heteroresi ...... teremia: trends over 11 years.
@en
P2093
Adina C Musta
Jinson Jose
Kathleen Riederer
Leonard B Johnson
Patrick Chase
Riad Khatib
Stephen Shemes
P2860
P304
P356
10.1128/JCM.02135-08
P407
P577
2009-04-15T00:00:00Z